Cargando…

Prevention of venous thromboembolism with enoxaparin in bariatirc surgery

PURPOSE: Venous thromboembolism (VTE) after bariatric surgery is a significant cause of morbidity and mortality. Current modalities of thromboprophylaxis include subcutaneous injection of unfractionated or low-molecular-weight heparin (LMWH), pneumatic compression, elastic stockings, and inferior ve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Woo, Hee Doo, Kim, Yong Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Surgical Society 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641370/ https://www.ncbi.nlm.nih.gov/pubmed/23646316 http://dx.doi.org/10.4174/jkss.2013.84.5.298

Ejemplares similares

Efficacy and Safety of Enoxaparin for Preventing Venous Thromboembolic Events following Urologic Laparoscopic Surgery
por: Nomura, Takeo, et al.
Publicado: (2013)

Cost-Effectiveness Rivaroxaban versus Enoxaparin for Prevention of Venous Thromboembolism after Knee Replacement Surgery in Iran
por: Abutorabi, Ali, et al.
Publicado: (2023)

Ethical Concerns Regarding High-Dose Enoxaparin for Venous Thromboembolism Prevention in Plastic Surgery Patients
por: Swanson, Eric
Publicado: (2019)

The use of enoxaparin as venous thromboembolism prophylaxis in bariatric surgery: A retrospective cohort study
por: Altawil, Esraa, et al.
Publicado: (2022)

Safety of Enoxaparin as Venous Thromboembolism Prophylaxis After Rhytidectomy
por: Lisiecki, Jeffrey L., et al.
Publicado: (2019)

Bemiparin versus Enoxaparin in the Prevention of Venous Thromboembolism among Intensive Care Unit Patients
por: Abbas, Mohamed Sayed
Publicado: (2017)

Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in Low Body Weight Patients
por: Dybdahl, Daniel, et al.
Publicado: (2019)

Optimal Dosing of Enoxaparin in Critically Ill Patients with Venous Thromboembolism
por: Abdulla, Aliya, et al.
Publicado: (2023)

Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study
por: Trujillo‐Santos, Javier, et al.
Publicado: (2022)

Comparison of the Efficacy and Safety of Aspirin and Rivaroxaban Following Enoxaparin Treatment for Prevention of Venous Thromboembolism after Hip Fracture Surgery
por: Huang, Qiang, et al.
Publicado: (2019)

Biosimilar versus branded enoxaparin to prevent postoperative venous thromboembolism after surgery for digestive tract cancer: Randomized trial
por: Dziri, Chadli, et al.
Publicado: (2023)

Rivaroxaban versus enoxaparin for the prevention of recurrent venous thromboembolism in patients with cancer: A meta-analysis
por: Xing, Jiali, et al.
Publicado: (2018)

Abstract: Venous Thromboembolism Prevention Using Twice Daily Enoxaparin in Plastic Surgery Patients: A Prospective Clinical Trial
por: Pannucci, Christopher J., et al.
Publicado: (2017)

Dabigatran versus Enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: A randomized clinical trial
por: Mirdamadi, Ahmad, et al.
Publicado: (2014)

Benefit–risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty
por: Levitan, Bennett, et al.
Publicado: (2014)

Fondaparinux vs. enoxaparin for the prevention of venous thromboembolism after total hip replacement: A meta-analysis
por: Dong, Wen-Jun, et al.
Publicado: (2016)

Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total knee arthroplasty: A meta-analysis
por: Huang, Hai-Feng, et al.
Publicado: (2018)

Direct Oral Anticoagulants Vs. Enoxaparin for Prevention of Venous Thromboembolism Following Orthopedic Surgery: A Dose–Response Meta‐analysis
por: Boyd, RA, et al.
Publicado: (2017)

The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients
por: Pineo, Graham F, et al.
Publicado: (2012)

Current status of venous thromboembolism development during the perioperative period for colorectal cancer, its prevention with enoxaparin, and monitoring methods
por: Aoki, Jun, et al.
Publicado: (2019)

Meta regression analysis to indirectly compare dalteparin to enoxaparin for the prevention of venous thromboembolic events following total hip replacement
por: Dranitsaris, George, et al.
Publicado: (2011)

Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V
por: Fuji, Takeshi, et al.
Publicado: (2015)

Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial
por: Guntupalli, Saketh R., et al.
Publicado: (2020)

Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment
por: Bauersachs, Rupert M, et al.
Publicado: (2014)

Comparison of Efficacy and Safety of Two Different Enoxaparin Products in Prevention of Venous Thromboembolism Following Major Obstetric-gynecological Surgeries: An Open-label Randomized Clinical Trial
por: Abdolvand, Manoochehr, et al.
Publicado: (2019)

Assessment of anti-factor Xa activity of enoxaparin for venous thromboembolism prophylaxis in morbidly obese surgical patients
por: Al Otaib, Nouf, et al.
Publicado: (2017)

742 Evaluation of Anti-Xa Levels and Venous Thromboembolism Prophylaxis with Enoxaparin in Burn Patients
por: Boyd, Allison, et al.
Publicado: (2023)

Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome—A Single Center Prospective Study
por: Matyjek, Anna, et al.
Publicado: (2021)

Reduced dosing of enoxaparin for venous thromboembolism in overweight and obese adolescents: a single institution retrospective review
por: Hoffman, Stephanie, et al.
Publicado: (2017)

Efficacy and Safety of a Biosimilar Versus Branded Enoxaparin in the Prevention of Venous Thromboembolism Following Major Abdominal Surgery: A Randomized, Prospective, Single-Blinded, Multicenter Clinical Trial
por: Ramacciotti, Eduardo, et al.
Publicado: (2018)

Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial: Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial)
por: Longo de Oliveira, André Luiz Malavasi, et al.
Publicado: (2022)

Intermittent pneumatic compression versus additional prophylaxis with enoxaparin for prevention of venous thromboembolism after laparoscopic surgery for gastric and colorectal malignancies: multicentre randomized clinical trial
por: Kamachi, H., et al.
Publicado: (2020)

Value of venous thromboembolism prophylaxis by enoxaparin with anti-factor Xa trough concentration monitoring in surgical care
por: Zachariah, Seeba, et al.
Publicado: (2020)

Safety and Effectiveness of Reduced Dose Versus Standard Dose Enoxaparin Venous Thromboembolism Prophylaxis in Underweight Medically Ill Patients
por: Nemeth, Abigail, et al.
Publicado: (2022)

Oral dabigatran etexilate versus enoxaparin for venous thromboembolism prevention after total hip arthroplasty: pooled analysis of two phase 3 randomized trials
por: Eriksson, Bengt I., et al.
Publicado: (2015)

Use of Enoxaparin to Counteract COVID-19 Infection and Reduce Thromboembolic Venous Complications: A Review of the Current Evidence
por: Drago, Filippo, et al.
Publicado: (2020)

New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism
por: Kim, Joo Hee, et al.
Publicado: (2017)

Risk of venous thromboembolism, use of enoxaparin and clinical outcomes in obese patients undergoing laparoscopic adjustable gastric band surgery: A retrospective study
por: Hussain, Zahid, et al.
Publicado: (2020)

Anti-Factor Xa Levels in Low-weight Surgical Patients Receiving Enoxaparin for Venous Thromboembolism Prophylaxis: A Prospective Cohort Study
por: Hakeam, Hakeam A., et al.
Publicado: (2020)

Higher Adherence to Treatment With Low-Molecular-Weight-Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancer-Associated Venous Thromboembolism
por: van der Wall, Sake J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8gio2k83n5fs2ta8090o9jqp7a